Quanticate CRO Blog

Your SAS Secrets Exposed! [4 SAS Tips]

Posted by Clinical Programming Team on Tue, Jul 14, 2015

SAS_Tips

During my time in the life science industry I have learnt a lot of SAS techniques through attending training sessions, however some of the best SAS tips I have picked up were from other programmers: for instance when asking for advice on a coding problem or running programs written by colleagues. I found there are many simple SAS® tips you can use in your day to day SAS programming. This blog will provide explanations and examples of four of these.

Read More

Tags: Clinical Programming, SAS Programming, SAS Datasets, SAS Macros

7 Considerations of Global Resources in Clinical Development Partnerships

Posted by Daniel Chapple on Fri, May 29, 2015

 

The second blog post in our “How Total Value Ownership (TVO) can help shape an outsourcing strategy" blog series.


Project costs in clinical development partnerships can be influenced significantly by the location of staff since salary levels differ widely depending on where the staff members are located. The percentage and mix of staff in different locations can provide a cost-effective solution, but it can also provide a solution that compromises quality if the mix is not right. Whilst the initial costs may decrease and help to build a business case, the Total Value Ownership (TVO) may not look so attractive when taking into account the oversight and other costs associated with the deliverables. Any projects that move off their critical paths can also have significant impacts to the overall TVO, particularly if this results in delays of submissions and ultimately launch. 

Read More

Tags: Clinical Trials, CRO Selection, Strategic Resourcing, CRO Project, Quality Control, CRO Efficiency, Project Management, Offshore Locations, Functional Outsourcing, FSP, Total Value Ownership

Nick Burch Discusses Big Data in Clinical Trials [Video]

Posted by Nick Burch on Fri, Apr 24, 2015

Nick Burch, CTO at Quanticate discussed Big Data in Clinical Trials at the 4th Annual Clinical Data Integration and Management conference this year in Princeton, NJ. His presentation is titled: 'The Myth of the Big Data Silver Bullet - Why Requirements Still Matter'

Abstract

We've all heard the hype - Big Data will solve all your storage, processing and analytic problems effortlessly! Some moving beyond the buzzwords find things really do work well, but others rapidly run into issues. The difference usually isn't the technologies or the vendors per-se, but their appropriateness to the requirements, which aren't always clear up-front.

Big Data, and the related area of NoSQL, are actually a broad range of technologies, solutions and approaches, with varying levels of overlap. Sadly it's not just enough to pick "a" Big Data solution, it needs to be the right one for your requirements. In this talk, we'll first do a whistle-stop tour of the different broad areas and approaches of the Big Data space. Then, we'll look at how Quanticate selected and built our Big Data platform for clinical data, driven by the needs and requirements. We won't tell you what Big Data platform you yourself need, but instead try to help you with the questions you need to answer to derive your own requirements and approach, from which your successful Big Data in clinical trials solution can emerge!

 

Big Data in Clinical Trials Video 

 

Read More

Tags: Clinical Trials, Clinical Data Storage, FDA, Clinical Study Design, Large Datasets, CRO Efficiency, Visualization, Accessible Data, Mobile Device, Big Data, Drug Development, Technology Trends

Remote Monitoring During Clinical Trials, a Risk based Approach

Posted by Medical Writing Team on Fri, Apr 10, 2015

 

Within the last few decades the number and complexity of clinical trials has increased considerably, not only across the industry but within individual companies.  With this increase comes the enhanced pressure of effectively monitoring these trials.

Read More

Tags: Regulatory Requirements, Clinical Trials, Good Clinical Practice (GCP), Clinical Data Storage, Case Report Form (CRF), Remote Monitoring, Adverse Events (AEs), Ethics, On-Site Monitoring

The Creation of ADaM Datasets for Pharmacokinetic (PK) Analysis [Video]

Posted by Clinical Programming Team on Thu, Mar 26, 2015

In this recorded presentation a member of the Quanticate's Clinical Programming Team explores the creation of two ADaM datasets; ADPC and ADPP for Pharmacokinetic (PK) Analysis.

 

Read More

Tags: Pharmacokinetics and Pharmacodynamic, CDISC Guidelines, CDISC SDTM, SDTM Domains, CDISC, Clinical Programming, SDTM, CDISC Standards, PK Analysis, ADaM Datasets

Total Value Ownership of selecting a partner for Clinical Development

Posted by Daniel Chapple on Mon, Mar 16, 2015

The first blog post in our “How Total Value Ownership (TVO) can help shape an outsourcing strategy" blog series.

 

Total Value Ownership (TVO) is not a new concept but it is an area that has attracted much interest in recent years. It can help in determining the best approaches to take and suppliers to use, by demonstrating the real value of selecting a certain partner in clinical development.

Read More

Tags: CRO Selection, Outsourcing Solutions, CRO Project, CRO Efficiency, Clinical Research Organization, Clinical Data Services, Functional Outsourcing, Total Value Ownership

Ben Goldacre Discusses Clinical Data Transparency [Video]

Posted by Statistical Consultancy Team on Mon, Feb 23, 2015

Dr Ben Goldacre, author of 'Bad Pharma' presented a keynote speech at the Clinical Data Live! symposium on clinical data transparency. 

Read More

Tags: Regulatory Requirements, Good Clinical Practice (GCP), FDA, Electronic Medical Record (EMR), Adverse Events (AEs), Historical Data, European Medicines Agency, Clinical Trial Documentation, Clinical Documents, Ethics, Accessible Data, Data Transparency

An Overview of Efficacy Endpoints in Oncology Studies

Posted by Clinical Programming Team on Fri, Jan 09, 2015

This blog provides an overview of efficacy endpoints in oncology studies. We will focus on RECIST (Response Evaluation Criteria In Solid Tumours).This is a method of assessing how solid tumours change over the course of a study. We will cover the measurements taken for RECIST assessments (Target lesions, Non target lesions, New lesions) and the possible outcomes, (complete response, partial response, stable disease, progressive disease) and what they mean – for example; patient recovered, stayed the same or got worse. We will also cover how visit windows and censoring can be handled. How and why measurement methods are important.  We will cover other endpoints relevant to oncology such as Overall survival, Objective Response Rate, Best overall response, Disease control at X weeks and quality of life.

Read More

Tags: Clinical Programming, Ethics, Oncology

How will the change in European Device Regulations affect vigilance practices?

Posted by Pharmacovigilance Team on Thu, Dec 11, 2014

On 22 October 2013 the European Parliament agreed to new proposals for regulation on Medical Devices and in vitro diagnostic medical devices. Outdated legislation and high profile scandals have made changes a necessity. This is despite disagreements between legislators and industry over the content of the new legislation. But how will this impact vigilance practices and will it stop medical device scandals from ever happening again?

Read More

Utilizing a Bayesian Informative Prior to Reduce Sample Size in Clinical Trials

Posted by Statistical Consultancy Team on Thu, Nov 13, 2014

Bayesian statistics in clinical trials are becoming more widely used in the pharmaceutical industry. By gathering data from historical studies, it is possible to reduce the sample size of the current trial by using an informative prior in the Bayesian analysis. This blog explores five cases in different indications that have historical data on placebo subjects from the literature, and calculates the effective sample size using an informative prior. In some cases, the effective sample size is substantial, but in others there are no sample size savings despite abundant data in the literature.

Read More

Tags: Bayesian Statistics, Bayesian Methods, Statistical Programming, Biostatistics Consulting